These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38450878)

  • 1. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.
    Ezekowitz J; Alemayehu W; Edelmann F; Ponikowski P; Lam CSP; O'Connor CM; Butler J; Corda S; McMullan CJ; Westerhout CM; Voors AA; Mentz RJ; Armstrong PW;
    Eur J Heart Fail; 2024 Mar; 26(3):628-637. PubMed ID: 38450878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
    Lam CSP; Giczewska A; Sliwa K; Edelmann F; Refsgaard J; Bocchi E; Ezekowitz JA; Hernandez AF; O'Connor CM; Roessig L; Patel MJ; Pieske B; Anstrom KJ; Armstrong PW;
    JAMA Cardiol; 2021 Jun; 6(6):706-712. PubMed ID: 33185650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.
    Coiro S; Girerd N; McMurray JJV; Pitt B; Swedberg K; van Veldhuisen DJ; Lamiral Z; Rossignol P; Zannad F
    Clin Res Cardiol; 2021 Aug; 110(8):1308-1320. PubMed ID: 33956209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
    Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
    JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loop diuretic down-titration at discharge in patients hospitalized for acute heart failure.
    Croset F; Llàcer P; Núñez J; Campos J; García M; Pérez A; Fernández C; Fabregate M; López G; Tello S; Fernández JM; Ruiz R; Manzano L
    ESC Heart Fail; 2024 Jun; 11(3):1739-1747. PubMed ID: 38454739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Loop and Thiazide Diuretics Across the Left Ventricular Ejection Fraction Spectrum: The CLOROTIC Trial.
    Sánchez-Marteles M; Garcés-Horna V; Morales-Rull JL; Casado J; Carrera-Izquierdo M; Conde-Martel A; Dávila-Ramos MF; Llácer P; Salamanca-Bautista P; Ruiz R; Aramburu-Bodas O; Formiga F; Manzano L; Trullàs JC
    JACC Heart Fail; 2024 Oct; 12(10):1719-1730. PubMed ID: 38934966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
    Shah SJ; Sharma K; Borlaug BA; Butler J; Davies M; Kitzman DW; Petrie MC; Verma S; Patel S; Chinnakondepalli KM; Einfeldt MN; Jensen TJ; Rasmussen S; Asleh R; Ben-Gal T; Kosiborod MN
    Eur Heart J; 2024 Sep; 45(35):3254-3269. PubMed ID: 38739118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Chatur S; Vaduganathan M; Claggett B; Vardeny O; Desai AS; Jhund PS; de Boer RA; Lam CSP; Kosiborod MN; Shah SJ; Martinez F; Inzucchi SE; Hernandez AF; Haddad T; Mitter SS; Miao ZM; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
    Eur Heart J; 2023 Aug; 44(31):2930-2943. PubMed ID: 37220093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.
    Damman K; Kjekshus J; Wikstrand J; Cleland JG; Komajda M; Wedel H; Waagstein F; McMurray JJ
    Eur J Heart Fail; 2016 Mar; 18(3):328-36. PubMed ID: 26693947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
    Vardeny O; Claggett B; Kachadourian J; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2019 Mar; 21(3):337-341. PubMed ID: 30741494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low.
    Verbrugge FH; Martens P; Boonen L; Nijst P; Verhaert D; Noyens P; De Vusser P; Dupont M; Tang WHW; Mullens W
    Acta Cardiol; 2018 Aug; 73(4):335-341. PubMed ID: 28971753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit.
    Buckley LF; Carter DM; Matta L; Cheng JW; Stevens C; Belenkiy RM; Burpee LJ; Young MA; Weiffenbach CS; Smallwood JA; Stevenson LW; Desai AS
    JACC Heart Fail; 2016 Jan; 4(1):1-8. PubMed ID: 26656139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial.
    Khan MS; Butler J; Young R; Lewis BS; Escobedo J; Refsgaard J; Reyes E; Roessig L; Blaustein RO; Lam CSP; Voors AA; Ponikowski P; Anstrom KJ; Armstrong PW;
    JACC Heart Fail; 2024 Oct; 12(10):1750-1759. PubMed ID: 38934967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop.
    Orvin NJ; Beavers JC; Russell SD
    J Pharm Pract; 2022 Dec; 35(6):859-863. PubMed ID: 33882753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
    Ter Maaten JM; Martens P; Damman K; Dickstein K; Ponikowski P; Lang CC; Ng LL; Anker SD; Samani NJ; Filippatos G; Cleland JG; Zannad F; Hillege HL; van Veldhuisen DJ; Metra M; Voors AA; Mullens W
    Clin Res Cardiol; 2020 Aug; 109(8):1048-1059. PubMed ID: 32002631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.
    Chatur S; Claggett BL; Vardeny O; Jering K; Desai AS; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
    Eur J Heart Fail; 2023 Jan; 25(1):87-94. PubMed ID: 36181769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Armstrong PW; Pieske B; Anstrom KJ; Ezekowitz J; Hernandez AF; Butler J; Lam CSP; Ponikowski P; Voors AA; Jia G; McNulty SE; Patel MJ; Roessig L; Koglin J; O'Connor CM;
    N Engl J Med; 2020 May; 382(20):1883-1893. PubMed ID: 32222134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Mullens W
    Am J Cardiol; 2017 Jul; 120(2):267-273. PubMed ID: 28532770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.
    Brisco-Bacik MA; Ter Maaten JM; Houser SR; Vedage NA; Rao V; Ahmad T; Wilson FP; Testani JM
    J Am Heart Assoc; 2018 Sep; 7(18):e009149. PubMed ID: 30371181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.